Michael Christel

Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID—reinforcing the staying power of building brand value while championing medical innovation.

Our editorial team presents the winners of our annual Emerging Pharma Leaders and their up-and-coming perspectives on a range of industry topics.

Turning to a next-gen psoriasis treatment to help drive future fortunes.

Our 20th annual listing highlights brand surges, new ranking battles, and M&A-sparked upswings, but in the shadow of COVID-19, a peek behind the numbers also tells another story.

Jennifer Buell, chief operating officer at Agenus, discusses the need for additional immunotherapies and combination strategies in cancer-building on learnings from the first wave of immune checkpoint inhibitors.

With a growing abundance of clinical and health information now available and achievable, the need for industry to apply common structures and rules to interpret and act on this data is critical.

Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market.

DIA’s global chief executive talks with Pharm Exec about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its benefits in everyday practice.

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth in a potentially resurgent marketplace.

Markus Warmuth, CEO of cancer genomics company H3 Biomedicine, speaks with Pharm Exec about being part of a new wave of biotech business leaders, who let the science chart the course.